Male Hypogonadism Diagnostic Algorithm: Step by Step

Step 1: Identify Symptomatic Men Who Warrant Testing

The diagnostic process begins with clinical suspicion, not a lab order. A man presenting with reduced sexual desire, erectile dysfunction, fatigue, loss of body hair, decreased muscle mass, or depressed mood should be evaluated. The Endocrine Society's 2018 Clinical Practice Guideline recommends against screening asymptomatic men.

Sexual symptoms carry the strongest diagnostic weight. The European Male Ageing Study (EMAS), which followed 3,369 men ages 40 to 79, found that only three symptoms showed a syndromic association with low testosterone: decreased frequency of morning erections, decreased frequency of sexual thoughts, and erectile dysfunction [1]. The EMAS investigators concluded that "the presence of the three sexual symptoms in combination with total testosterone <11 nmol/L (317 ng/dL) and free testosterone <220 pmol/L provides a strong basis for diagnosing late-onset hypogonadism" [1].

Non-sexual symptoms such as fatigue and low mood are common in the general population and lack specificity on their own. A 2016 analysis in the Journal of Clinical Endocrinology & Metabolism showed that 20% of men over age 45 with fatigue as their sole complaint had total testosterone within the normal range [2]. Combining symptom history with validated questionnaires like the ADAM (Androgen Deficiency in the Aging Male) tool can increase clinical yield, although the ADAM questionnaire has a sensitivity of 88% but a specificity of only 60% [3].

Certain populations deserve heightened clinical attention. Men with type 2 diabetes have a hypogonadism prevalence of 25% to 40%, according to a meta-analysis published in Diabetes Care [4]. Men on chronic opioid therapy, those with HIV/AIDS, and those taking long-term glucocorticoids are also at elevated risk per AUA guidelines.

Step 2: Obtain a Fasting Morning Total Testosterone

Once symptoms warrant investigation, the first lab is a fasting morning total testosterone drawn between 7:00 and 10:00 AM. This timing matters. Testosterone follows a circadian rhythm, peaking in early morning and falling 20% to 25% by late afternoon in younger men [5]. The Endocrine Society guideline specifies morning collection to avoid false-positive low readings.

Fasting also matters. A 2013 study in Clinical Endocrinology demonstrated that glucose ingestion acutely suppresses serum testosterone by a mean of 25%, with levels remaining suppressed for up to 2 hours [6]. Drawing blood in a fed state can yield artificially low results that do not reflect the patient's true hormonal baseline.

The threshold most clinicians reference is 300 ng/dL (10.4 nmol/L), the lower limit established by the Endocrine Society. The CDC Hormone Standardization Project (HoSt) later proposed a harmonized lower cutoff of 264 ng/dL based on mass spectrometry assays in a healthy, non-obese reference population [7]. Both numbers appear in clinical practice. Laboratories using immunoassay platforms may report different reference ranges, which is why the method of measurement matters when interpreting borderline values.

A single low result does not confirm hypogonadism. Acute illness, sleep deprivation, extreme exercise, and medication effects can transiently suppress testosterone. Repeat testing is mandatory.

Step 3: Confirm With a Second Morning Testosterone

The Endocrine Society, AUA, and AACE all require at least two low morning testosterone values before establishing the diagnosis. The repeat draw should occur 2 to 4 weeks after the first test, again in a fasting state before 10:00 AM.

This confirmation step is not optional. A 2015 analysis in the Journal of Clinical Endocrinology & Metabolism found that 30% of men with an initial total testosterone below 300 ng/dL had a normal value on repeat testing [8]. The authors described this variability as reflecting both biological fluctuation and assay imprecision, and the finding underscores why single-draw diagnosis leads to overtreatment.

If the second value returns below 300 ng/dL and symptoms are present, the biochemical diagnosis is established. If the second value is normal, the diagnosis is not confirmed, and monitoring with symptom reassessment over 3 to 6 months is appropriate.

For men whose total testosterone falls in the borderline zone of 200 to 400 ng/dL, measuring free testosterone or bioavailable testosterone adds diagnostic clarity, particularly if conditions that alter sex hormone-binding globulin (SHBG) are present. Obesity lowers SHBG and can make total testosterone appear low while free testosterone remains normal. Aging, liver disease, and hyperthyroidism raise SHBG and can mask true hypogonadism behind a normal total testosterone reading.

Step 4: Classify as Primary or Secondary Hypogonadism

With two confirmed low testosterone values, the next step separates testicular failure from hypothalamic-pituitary dysfunction. This classification determines both the diagnostic workup and the treatment pathway. Order LH, FSH, and prolactin.

Primary hypogonadism (hypergonadotropic) presents with elevated LH and FSH because the pituitary gland is responding appropriately to low testosterone by increasing gonadotropin output. The testes are the point of failure. Common causes include Klinefelter syndrome (47,XXY, prevalence 1 in 660 males), prior chemotherapy or radiation, orchitis, testicular trauma, and bilateral cryptorchidism. A karyotype should be ordered in younger men with primary hypogonadism and small, firm testes.

Secondary hypogonadism (hypogonadotropic) presents with low or inappropriately normal LH and FSH. The hypothalamus or pituitary is not sending adequate stimulatory signals. Causes range from reversible factors (obesity, opioid use, hyperprolactinemia, exogenous androgens or anabolic steroids) to structural lesions (pituitary adenomas, infiltrative diseases, prior head trauma or surgery). The Endocrine Society guideline states: "In men with secondary hypogonadism, we recommend measuring serum prolactin, iron saturation, and other pituitary hormones."

A mixed picture, with partially elevated gonadotropins and low testosterone, may indicate early or compensated primary hypogonadism or combined pathology. In older men, this pattern is often called "compensated hypogonadism" and its clinical significance remains an area of active research [9].

Step 5: Directed Secondary Workup Based on Classification

The workup now branches depending on the classification from Step 4.

For primary hypogonadism, consider karyotype analysis (especially in men under 40 or with testicular volumes below 6 mL), testicular ultrasound if a mass is suspected, and semen analysis if fertility is a concern. A 2019 meta-analysis in Human Reproduction Update found that 65% of men with Klinefelter syndrome present with azoospermia and that early diagnosis enables sperm-extraction options that improve fertility outcomes [10].

For secondary hypogonadism, the evaluation targets the hypothalamic-pituitary axis. Serum prolactin is essential. A prolactin level above 250 ng/mL strongly suggests a macroprolactinoma, while mild elevations (25 to 100 ng/mL) can result from medications such as antipsychotics or from the "stalk effect" of a non-functioning pituitary mass compressing the infundibulum. Pituitary MRI with gadolinium contrast is recommended when prolactin is elevated, total testosterone is below 150 ng/dL, or other pituitary hormone deficiencies are found.

Iron studies (serum ferritin and transferrin saturation) screen for hereditary hemochromatosis, a frequently overlooked cause of secondary hypogonadism. Iron overload preferentially deposits in the anterior pituitary and can destroy gonadotroph cells. A ferritin above 300 ng/mL in a man with secondary hypogonadism warrants HFE gene testing [11].

Other pituitary hormones to evaluate include cortisol (8 AM level or ACTH stimulation test), TSH and free T4, and IGF-1 as a surrogate for growth hormone status. These help rule out panhypopituitarism and guide the scope of treatment.

Step 6: Evaluate Reversible Contributors Before Treating

Treatment should not begin before addressing reversible causes. This step is frequently shortchanged in clinical practice but can eliminate the need for lifelong testosterone therapy in a meaningful subset of patients.

Obesity is the most common modifiable contributor. The Massachusetts Male Aging Study demonstrated that a 4 to 5 kg/m² increase in BMI produced a testosterone decline equivalent to 10 years of aging [12]. Weight loss of 5% to 10% body weight through lifestyle intervention or GLP-1 receptor agonist therapy has been shown to raise total testosterone by 50 to 100 ng/dL in obese men [13]. A 2022 post hoc analysis of the STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks, with secondary analyses reporting improved testosterone levels in men with obesity-related hypogonadism [14].

Medications that suppress the HPG axis include opioids (which reduce GnRH pulse frequency), glucocorticoids, and anabolic steroids. Opioid-induced androgen deficiency affects 19% to 86% of men on chronic opioid therapy depending on the dose and study population [15]. Tapering or rotating opioids, when medically feasible, may restore testosterone production.

Sleep apnea suppresses pulsatile LH release and is both a cause and consequence of low testosterone. The AACE 2020 guidelines recommend evaluating all hypogonadal men for obstructive sleep apnea using the STOP-BANG questionnaire before initiating testosterone replacement.

Addressing these factors first is not simply a clinical nicety. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 788 men aged 65 and older with testosterone below 275 ng/dL, demonstrated that while testosterone gel improved sexual function, physical activity, and mood, benefits were modest and did not persist uniformly across all endpoints after treatment cessation [16]. Treating the root cause, when one exists, may produce more durable results.

Step 7: Decide on Testosterone Therapy and Monitor

When hypogonadism is confirmed, classified, and reversible factors have been addressed or ruled out, testosterone replacement therapy (TRT) becomes the primary intervention for symptomatic men who are not seeking fertility.

The Endocrine Society 2018 guideline recommends TRT for men with consistently low testosterone and unambiguous symptoms, provided there are no contraindications. Absolute contraindications include metastatic prostate cancer, breast cancer, unevaluated prostate nodule or PSA above 4 ng/mL (or above 3 ng/mL in high-risk men), hematocrit above 50%, untreated severe obstructive sleep apnea, uncontrolled heart failure, and desire for fertility within the near term (since exogenous testosterone suppresses spermatogenesis).

Available formulations include intramuscular injections (testosterone cypionate or enanthate 100 to 200 mg every 1 to 2 weeks), transdermal gels (testosterone 1% gel, 50 to 100 mg daily), transdermal patches, nasal testosterone (Natesto, 11 mg per nostril three times daily), subcutaneous pellets (Testopel, 150 to 450 mg every 3 to 6 months), and oral testosterone undecanoate (Jatenzo, 158 to 396 mg twice daily with food). The AUA guideline panel noted that "choice of testosterone formulation should be a shared decision based on patient preference, pharmacokinetics, cost, and the formulation's adverse-effect profile" [17].

Monitoring on TRT follows a standardized schedule:

• Total testosterone and hematocrit at 3 to 6 months, then annually
• PSA and digital rectal exam at 3 to 12 months, then per age-appropriate screening guidelines
• Bone density (DXA) at baseline and 1 to 2 years for men with osteoporosis
• Lipid panel and metabolic markers annually

The goal is to maintain midnormal testosterone levels (450 to 600 ng/dL). The TRAVERSE trial (N=5,204), the largest randomized cardiovascular safety trial of testosterone therapy, demonstrated that testosterone replacement did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo in men ages 45 to 80 with cardiovascular disease or elevated cardiovascular risk (hazard ratio 0.96, 95% CI 0.78 to 1.17) [18].

When to Refer to Endocrinology

Not every case of low testosterone requires specialist input, but certain scenarios demand referral. Men under 30 with confirmed hypogonadism, suspected pituitary pathology (abnormal MRI, panhypopituitarism, or prolactin above 100 ng/mL), Klinefelter syndrome, desire for fertility with concurrent hypogonadism, or testosterone levels below 150 ng/dL without an obvious reversible cause should be evaluated by a reproductive endocrinologist or endocrinologist.

For men wanting both symptom relief and preserved fertility, alternatives to exogenous testosterone include clomiphene citrate (25 to 50 mg daily, off-label), human chorionic gonadotropin (hCG, 1,500 to 3,000 IU two to three times weekly), or combination protocols. A 2020 retrospective analysis in the Journal of Urology found that clomiphene citrate raised total testosterone by a mean of 271 ng/dL (from a baseline of 228 ng/dL) while maintaining or improving sperm concentration in 86% of men [19].

The diagnostic algorithm for male hypogonadism, from symptom identification through classification and directed workup, ensures accurate diagnosis before committing a patient to treatment. Skipping steps leads to either missed treatable causes or unnecessary lifelong therapy. Every man with confirmed hypogonadism should have a documented answer to three questions: Is the testosterone truly low? Is it primary or secondary? Are there reversible contributors? Only after all three are answered does the treatment conversation begin.